Temozolomide

Generic Name: Temozolomide

Brand Names: Temodar, Temomedac, Temodal, Temozolomide Sun, Temozolomide Accord, Temozolomide Teva

Drug Type: Small Molecule

Chemical Formula: C_₆H_₆N_₆O_₂

CAS Number: 85622-93-1

Unique Ingredient Identifier: YF1K15M17Y

Background: Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alkylating agents, although they invariably ...

Indication: Temozolomide is indicated in adult patients for the treatment of newly diagnosed glioblastoma concomitantly with radiotherapy and for use as maintenance treatment thereafter. It is also indicated for the treatment of refractory anaplastic astrocytoma in adult patients or adjuvant therapy for adults with newly diagnosed anaplastic astrocytoma.

Associated Conditions: Advanced Melanoma, High Grade Glioma: Glioblastoma (GBM), Primary Central Nervous System Lymphoma, Refractory Ewing Sarcoma, Refractory Neuroblastoma, Soft Tissue Sarcoma, Advanced Neuroendocrine tumor, Newly diagnosed Anaplastic Astrocytoma (AA), Refractory Anaplastic astrocytoma, Refractory, advanced Mycosis fungoides, Refractory, advanced Sezary Syndrome

Associated Therapies: -

Clinical Trials

Temozolomide in Treating Patients With Mycosis Fungoides or Sezary Syndrome

Phase 2

Terminated

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2012-06-06

Lead Sponsor: Northwestern University

Target Recruit Count: 29

Registration Number: NCT00004106

Locations: 🇺🇸
Yale Comprehensive Cancer Center at Yale University School of Medicine, New Haven, Connecticut, United States
🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States

S9926 Temozolomide in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors

Phase 2

Completed

Conditions: Gastrointestinal Stromal Tumor

Interventions: Drug: temozolomide

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-03

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 25

Registration Number: NCT00005597

Locations: 🇺🇸
MBCCOP - Gulf Coast, Mobile, Alabama, United States
🇺🇸
CCOP - Beaumont, Royal Oak, Michigan, United States
🇺🇸
Veterans Affairs Medical Center - West Los Angeles, Los Angeles, California, United States

and more 103 locations

Temozolomide With or Without Radiation Therapy to the Brain in Treating Patients With Stage IV Melanoma That Is Metastatic to the Brain

Phase 3

Terminated

Conditions: Melanoma (Skin)
Metastatic Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2012-09-24

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 23

Registration Number: NCT00020839

Locations: 🇬🇧
Addenbrooke's NHS Trust, Cambridge, England, United Kingdom
🇬🇧
Royal Marsden NHS Trust, London, England, United Kingdom
🇨🇭
UniversitaetsSpital, Zurich, Switzerland

and more 30 locations

Chemotherapy and Radiation Therapy After Surgery in Treating Children With Newly Diagnosed Astrocytoma, Glioblastoma Multiforme, Gliosarcoma, or Diffuse Intrinsic Pontine Glioma

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors

Interventions: Drug: temozolomide
Procedure: adjuvant therapy
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2014-02-21

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 170

Registration Number: NCT00028795

Locations: 🇺🇸
Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
University of Illinois Medical Center, Chicago, Illinois, United States

and more 226 locations

Biological Therapy and Temozolomide in Treating Patients With Metastatic Melanoma

Phase 1

Conditions: Melanoma (Skin)

First Posted Date: 2003-01-27

Last Posted Date: 2013-09-20

Lead Sponsor: St. Luke's Medical Center

Target Recruit Count: 18

Registration Number: NCT00016055

Locations: 🇺🇸
Vince Lombardi Cancer Clinic at Aurora St. Luke's Medical Center, Milwaukee, Wisconsin, United States

Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors

Phase 2

Completed

Conditions: Adult Giant Cell Glioblastoma
Adult Glioblastoma
Adult Gliosarcoma

Interventions: Drug: erlotinib hydrochloride
Radiation: 3-dimensional conformal radiation therapy
Drug: temozolomide

First Posted Date: 2003-01-27

Last Posted Date: 2013-08-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 171

Registration Number: NCT00039494

Locations: 🇺🇸
Graham Hospital Association, Canton, Illinois, United States
🇺🇸
Mcdonough District Hospital, Macomb, Illinois, United States
🇺🇸
Siouxland Regional Cancer Center, Sioux City, Iowa, United States

and more 136 locations

Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2003-01-27

Last Posted Date: 2018-06-27

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Registration Number: NCT00027625

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States

and more 8 locations

Temozolomide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Anaplastic Oligodendrogliomas or Mixed Anaplastic Oligoastrocytomas

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors

Interventions: Drug: temozolomide
Procedure: neoadjuvant therapy
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2020-10-22

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 42

Registration Number: NCT00033280

Locations: 🇺🇸
Mercy Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸
Mobile Infirmary Medical Center, Mobile, Alabama, United States
🇺🇸
CCOP - Marshfield Clinic Research Foundation, Marshfield, Wisconsin, United States

and more 36 locations

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Brain Cancer

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2003-01-27

Last Posted Date: 2011-03-28

Lead Sponsor: NYU Langone Health

Registration Number: NCT00025558

Locations: 🇦🇺
Princess Margaret Hospital for Children, Perth, Western Australia, Australia
🇺🇸
NYU Cancer Institute at New York University Medical Center, New York, New York, United States
🇺🇸
Columbus Children's Hospital, Columbus, Ohio, United States

and more 1 locations

Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2003-01-27

Last Posted Date: 2018-06-27

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Registration Number: NCT00006025

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
🇺🇸
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 6 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy